Evidence map›Paper›PMID 41574208›Full record

ArticleFrontiers in drug delivery2025

Anti-HER2-targeted therapies: effects on human

Carolin J Curtaz, Rebecca Gebert, Achim Wöckel, Patrick Meybohm, Malgorzata Burek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carolin J CurtazDepartment of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany.
Rebecca GebertDepartment of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany.
Achim WöckelDepartment of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany.
Patrick MeybohmDepartment of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany.
Malgorzata BurekDepartment of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic breast cancer is associated with very poor overall survival and a reduced quality of life. HER2-positive breast cancer forms brain metastases at the late stages. Established therapies such as trastuzumab, pertuzumab, trastuzumab/pertuzumab, lapatinib and tucatinib are widely used and are selectively toxic to HER2-positive breast cancer cell line. However, the effects of these therapies on the properties of the blood-brain barrier (BBB) remain unclear. We investigated this using an

Indexed as

BLECsbrain microvascular endothelial cellshCMEC/D3HER2-positive breast cancerlapatinibpertuzumabtrastuzumabtucatinib

Identifiers

PMID41574208
PMCPMC12819789

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.